From 1990 to 2021, the global age-standardized prevalence, mortality, and DALY rates for pulmonary arterial hypertension declined, with AAPCs of -0.03, -0.82, and -1.52, respectively.
Observational
Yes
Despite a decline in age-standardized rates, the absolute global burden of pulmonary arterial hypertension has increased from 1990 to 2021, driven by population growth and aging.
Effect estimate: AAPC -0.03, -0.82, and -1.52
Despite improvements in survival rates for pulmonary arterial hypertension (PAH), its contribution to the mortality from chronic diseases remains significant, imposing a substantial medical and economic burden on patients, families, healthcare systems, and society at large. We aim to assess the trend in the burden of PAH, and to provide a basis for the development of global prevention and control strategies and resource allocation to alleviate the global burden of PAH. This study is based on data from the Global Burden of Disease 2021 (GBD 2021). The study adopted prevalence, mortality, disability-adjusted life-years (DALYs), and corresponding average annual percentage changes (AAPCs) to assess the burden of PAH. Additionally, we used decomposition analysis to explore the effects of aging, population growth, and epidemiologic changes on PAH prevalence. Globally, the prevalent cases of PAH rose from 105,703 to 191,808, the number of deaths rose from 14,842 to 22,021, and the DALYs decreased from 687,419 to 642,104 between 1990 and 2021. The global overall age-standardized prevalence rate (ASPR), age-standardized mortality rate (ASMR), and the age-standardized DALY rate (ASDR) per 100,000 population from 1990 to 2021 exhibited a declining trend (AAPC = −0.03, AAPC = −0.82, and AAPC = −1.52, respectively). Despite the decline in age-standardized prevalence, the burden of PAH remains a significant concern, with notable differences in ASPR, ASMR, and ASDR observed between regions, countries, and socio-demographic index (SDI) quintiles.
Chen et al. (Mon,) conducted a observational in Pulmonary arterial hypertension. Time period (1990-2021) was evaluated on Age-standardized prevalence, mortality, and DALY rates (AAPC -0.03, -0.82, and -1.52). From 1990 to 2021, the global age-standardized prevalence, mortality, and DALY rates for pulmonary arterial hypertension declined, with AAPCs of -0.03, -0.82, and -1.52, respectively.